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Edited by Aleksander BenjakAbstract Prions are the infectious agents responsible for prion
diseases, which appear to be composed exclusively by the mis-
folded prion protein (PrPSc). The mechanism of prion transmis-
sion is unknown. In this study, we attempted to detect prions in
urine of experimentally infected animals. PrPSc was detected in
80% of the animals studied, whereas no false positives were ob-
served among the control animals. Semi-quantitative calculations
suggest that PrPSc concentration in urine is around 10-fold lower
than in blood. Interestingly, PrPSc present in urine maintains its
infectious properties. Our data indicate that low quantities of
infectious prions are excreted in the urine. These ﬁndings suggest
that urine is a possible source of prion transmission.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Prions are the infectious agents responsible for a group of
fatal neurodegenerative diseases, collectively called Transmis-
sible Spongiform Encephalopathies (TSEs) that aﬀect humans
and several species of mammals [1–3]. Creutzfeldt–Jakob dis-
ease (CJD) is the most common TSE in humans, and scrapie
in sheep, bovine spongiform encephalopathy (BSE) in cattle
and chronic wasting disease (CWD) in cervids are the most
prevalent prion diseases in animals [2]. Although prion dis-
eases are relatively rare in humans, the recent appearance of
variant CJD (vCJD), which is linked to consumption of BSE
contaminated food, have raised concern about a possible epi-
demic outbreak in the human population [4]. BSE is still a sig-
niﬁcant health and economical problem, and other animal
diseases have become a permanent source of concern. Scrapie,
for example, is endemic in various countries and CWD is
spreading dramatically fast among wild and captive cervids
in North America. Finally, it is now clear that vCJD can be
iatrogenically transmitted from human to human by blood
transfusion raising fears of a second wave of infection [5,6].
Unlike conventional infectious micro-organisms, the TSE
agent appears to be devoid of genetic material and instead
composed exclusively by a misfolded form of the prion protein
(PrPSc) [3]. PrPSc has the intriguing ability to replicate in the
body of infected individuals by propagating its misfolding to
the normal prion protein (PrPC) [3]. PrPSc is not only the main*Corresponding author.
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doi:10.1016/j.febslet.2008.08.003component of the infectious agent and the most likely trigger-
ing factor in brain damage, but it is also the only validated sur-
rogate biomarker for the disease and its sensitive detection is
critical for disease diagnosis and to prevent further spreading
of TSEs [7]. Currently, there is no validated method to detect
PrPSc. Hampering the eﬀorts to develop a reliable biochemical
diagnosis for TSEs is the fact that PrPSc quantity in peripheral
tissues or biological ﬂuids is extremely low and under the limit
of detection of standard techniques [7].
With the aim of facilitating PrPSc biochemical detection, we
have developed a novel technique that enables PrPSc ampliﬁ-
cation in the test tube. This method, termed protein misfold-
ing cyclic ampliﬁcation (PMCA), is based on converting large
amounts of PrPC triggered by undetectable quantities of
PrPSc [8]. In a cyclic manner, conceptually analogous to poly-
merase chain-reaction (PCR), PrPSc is incubated with excess
PrPC to enlarge the PrPSc aggregates, which are then soni-
cated to generate multiple smaller units for the continued for-
mation of new PrPSc [8]. The newly generated protein exhibits
the same biochemical and structural properties as brain-de-
rived PrPSc and strikingly it is infectious to wild-type animals,
producing a disease with similar characteristics to the illness
produced by brain-isolated prions [9]. PMCA is highly spe-
ciﬁc for detection of PrPSc and leads to several million folds
increase on sensitivity as compared to standard Western blot
assays [10,11]. The technology has been applied to replicate
the misfolded protein from diverse species [12] and has en-
abled detection of prions in the blood of infected animals,
both at the symptomatic and pre-symptomatic phases of the
disease [10,13].
Although the highest concentration of PrPSc is present in the
nervous system, its presence has been reported with a variable
degree of success in peripheral tissues, such as lymphoid or-
gans, peripheral nerves, skeletal muscle, kidney, mammary
glands, olfactory mucosa and CSF (for reviews, see
[7,14,15]). Blood and urine represent the ideal biological ﬂuids
for routine non-invasive diagnosis. Various reports of experi-
mental and natural transmission have shown that blood carries
infectivity (for reviews, see [6,15,16]) and as described above,
we have been able to detect successfully PrPSc in animal blood.
Although, experiments with urine have been for the most part
negative, recent studies reported very small infectivity titers in
urine of a tiny proportion of scrapie sick rodents [17,18]. How-
ever, PrPSc was not detected in these studies, presumably be-
cause the quantity secreted in the urine is below the limit of
detection of the technology employed. The main goal of the
current study is to attempt detection of PrPSc in urine of exper-
imentally infected animals using the highly sensitive PMCA
technology.blished by Elsevier B.V. All rights reserved.
3162 D. Gonzalez-Romero et al. / FEBS Letters 582 (2008) 3161–31662. Materials and methods
2.1. Sample collection and preparation
Urine from healthy and sick animals was collected using metabolic
cages. Sick and healthy animals were of similar age. Urine was pro-
cessed as schematically described in Fig. 1A. Brain tissue from healthy
hamsters was used in PMCA reactions as a substrate for ampliﬁcation.
To prepare brain homogenate, animals were ﬁrst perfused with phos-
phate-buﬀered saline (PBS) plus 5 mM EDTA prior to harvesting
the tissue. Ten percent brain homogenates (w/v) were prepared in con-
version buﬀer (PBS containing NaCl 150 mM, 1.0% Triton X-100,
4 mM EDTA and the Complete Protease Inhibitor Cocktail from
Roche, Switzerland). The samples were clariﬁed by a brief, low-speed
centrifugation (2000 rpm for 40 s) using an Eppendorf centrifuge
(Hamburg, Germany), model 5414. Samples were stored frozen at
80 C.
2.2. PMCA procedure
Urine samples after the processing described in Fig. 1A were resus-
pended into 10% healthy brain homogenate. Samples were loaded onto
0.2-ml PCR tubes and positioned on an adaptor placed on the plate
holder of a microsonicator (Misonix Model 3000, Farmingdale,
NY). Each PMCA cycle consisted of 30 min incubation at 37 C fol-
lowed by a 20 s pulse of sonication set at potency of 7. Samples were
incubated without shaking immersed in the water of the sonicator
bath. The microplate horn was kept in an incubator set at 37 C during
the whole process. After a round of 96 cycles, an aliquot of the ampli-
ﬁed material was diluted 10-folds into normal brain homogenate and a
new round of 96 PMCA cycles was performed. This procedure was re-Fig. 1. Identiﬁcation of the experimental conditions to process urine sampl
symptomatic stage of the disease (and uninfected controls) produced by i.p.
milliliters of urine was pooled and processed as schematically illustrated in pa
to remove debris. The supernatant was collected and divided into two groups:
30000 Da cutoﬀ; the other sample was left untreated. Both samples were divi
volume of 20% sarkosyl and the other one was left untreated. After 30 min in
at 4 C. Pellet of each sample was resuspended directly in 80 ll of 10% nor
(30 min incubation at 37 C followed by a pulse of 30 s sonication, as descr
normal brain homogenate and a new round of 96 PMCA cycles was performe
20 ll of the sample was used for detection of PrPSc by Western blot after PK d
the results of serial rounds 5 and 6 of PMCA. No signal was observed before
animals. All samples were treated with PK before electrophoresis, except thpeated several times as indicated in the text. The detailed protocol for
PMCA, including reagents, methods and troubleshooting, has been
published elsewhere [19,20].2.3. PrPScdetection
Samples were incubated with 50 lg/ml of PK for 60 min at 45 C
with shaking. The digestion was stopped by adding electrophoresis
sample buﬀer. Proteins were fractionated by sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis (SDS–PAGE) under reduc-
ing conditions, electroblotted into nitrocellulose membrane, and
probed with 3F4 antibody (Signet, Dedham, MA) diluted 1:5000 in
PBS, 0.05% Tween-20. The immunoreactive bands were visualized by
enhanced chemoluminescence assay (Amersham, Piscataway, NJ).
Western blots signals were analyzed by densitometry, using a UVP
Bioimaging system EC3 apparatus (Upland, CA).2.4. In vivo infectivity studies
Syrian Golden hamsters were used as an experimental model of scra-
pie. Animals were 4–6-weeks old at the time of inoculation. For urine
collection animals were injected i.p. with 100 ll of 10% brain homog-
enate. To assess infectivity, anesthesized animals were injected stereo-
taxically into the right hippocampus with 2 ll of the sample. The onset
of clinical disease was measured by scoring the animals twice a week
using the following scale: (1) normal animal; (2) mild behavioral
abnormalities including hyperactivity and hypersensitivity to noise;
(3) moderate behavioral problems including tremor of the head, ataxia,
wobbling gait, head bobbing, irritability and aggressiveness; (4) severe
behavioral abnormalities including all of the above plus jerks of thees for PrPSc detection by PMCA. Urine from several hamsters at the
inoculation of 263K prions was collected with metabolic cages. Twelve
nel (A) First, urine was centrifuged at a low speed (5000 · g for 20 min)
one was dialyzed overnight against PBS at 4 C using a membrane with
ded into two identical aliquots, one of which was supplemented with 1
cubation at 4 C, all the samples were centrifuged at 100000 · g for 1 h
mal hamster brain homogenate and subjected to 96 cycles of PMCA
ibed in Section 2). Then, 8 ll of this sample were diluted into 72 ll of
d. This process was repeated several times. After each round of PMCA,
igestion (50 lg/ml for 1 h at 37 C), using 3F4 antibody. Panel B shows
the ﬁfth round. S: samples from sick animals; C: samples from control
e normal brain homogenate (NBH) in which –PK is indicated.
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the disease in which the animal lies in the cage and is no longer able
to stand up. Animals scoring level 4 during two consecutive weeks were
considered sick and were sacriﬁced to avoid excessive pain using expo-
sition to carbonic dioxide. Brains were extracted and one hemisphere
was frozen for biochemical studies and the other was used for histolog-
ical analysis. The scrapie infectious material used in these studies was
titrated and 1 LD50 was obtained in a brain dilution of approximately
1 · 109.
2.5. Histopathological studies
Brain tissue was ﬁxed in 10% formaldehyde solution, cut in sections
and embedded in paraﬃn. Serial sections (6 lm thick) from each block
were stained with hematoxylin–eosin, or incubated with monoclonal
antibodies recognizing PrP or the glial ﬁbrillary acidic protein, using
our previously described protocols [9]. Immunoreactions were devel-S1 C1 C2 C3 S2 S3
S1 C1 C2 C3 S2 S3
S1 C1 C2 C3 S2 S3
S1 C1 C2 C3 S2 S
5th round
6th round
7th round
8th round
Fig. 2. PrPSc detection in urine of sick hamsters by PMCA. Three milliliters o
and ﬁve control animals was collected using metabolic cages. The samples w
5000 · g for 20 min to remove debris. The supernatant was collected and su
precipitate PrPSc. Pellet was resuspended directly in 80 ll of 10% normal ham
cycles of PMCA, as described [10,11]. Twenty microliters of the sample was us
shows only the rounds 5, 6, 7 and 8, since the ﬁrst four rounds of PMCA d
PMCA do not show any more positive signals. S: samples from sick animal
before electrophoresis, except the normal brain homogenate (NBH) in whichoped using the peroxidase–antiperoxidase method, following manufac-
turers speciﬁcations. Antibody speciﬁcity was veriﬁed by absorption.
Samples were visualized with a Zeiss microscope.3. Results
In order to attempt PrPSc detection using PMCA, we col-
lected urine from several hamsters at the symptomatic phase
of the disease produced by intraperitoneal (i.p.) inoculation
of 263K prions. First, we tested several experimental condi-
tions to process urine samples for PrPSc detection by PMCA.
Urine from either sick or control animals was collected using
metabolic cages. Samples were pooled and processed as de-C4 S4 S5 C5
C4 S4 S5 C5
C4 S4 S5 C5
3 C4 S4 S5 C5
NBH
-PK
NBH
-PK
NBH
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f urine from ﬁve clinically sick hamsters (infected i.p. with HY prions)
ere processed as described in Fig. 1A. Brieﬂy, urine was centrifuged at
bjected to a high speed centrifugation at 100000 · g for 1 h at 4 C to
ster brain homogenate. Samples were subjected to serial rounds of 96
ed for detection of PrPSc by Western blot after PK digestion. The ﬁgure
id not show signal in any of the samples. More than seven rounds of
s; C: samples from control animals. All samples were treated with PK
–PK is indicated.
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including combinations between dialysis and sarkosyl precipi-
tation. After processing, the samples were subjected to several
rounds of 96 cycles of PMCA as described in Section 2. After
each round of PMCA, 20 ll of the sample was used for detec-
tion of PrPSc by Western blot after PK digestion. As shown in
Fig. 1B, after 6 serial rounds of PMCA, PrPSc was detectable
in 3 of the 4 conditions tested. The conclusion of these results
is that a simple high speed centrifugation, after removing large
debris, is suﬃcient to obtain an adequate sample. Neither the
dialysis nor the sarkosyl precipitation steps gave better results
in terms of PMCA ampliﬁcation.
To evaluate the presence of PrPSc in individual samples of
urine, we collected urine from ﬁve scrapie sick animals i.p. in-
fected by the hamster strain Hyper (HY) as well as control un-
infected animals of similar age. As before, several serial rounds
of PMCA were unsuccessful to detect PrPSc in any of the urine
samples tested. However, after 6, 7 or 8 rounds of 96 PMCA
cycles each, we were able to detect a PrPSc signal by Western
blot in the urine of 3 or 4 of the 5 animals studied, respectively
(Fig. 2). Conversely, PrPSc was not detected in the urine of any
of the ﬁve control uninfected hamsters tested, indicating that
the procedure is speciﬁc for detection of prion infected sam-
ples. These results indicate that PMCA enable detection of
PrPSc in urine of scrapie sick hamsters with 80% sensitivityHY brain
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Fig. 3. Urinary PrPSc is infectious. To assess whether PrPSc ampliﬁed
from urine maintain the infectious properties, we inoculated intra-
cerebrally ﬁvewild-type hamsters with the sample S4 in Fig. 2 after seven
serial rounds of PMCA.As controls, groups of hamsters were inoculated
with equivalent quantities of brain-derived HY PrPSc and PMCA-
generated PrPSc starting from HY brain. The later was generated as
previously described [9]. Brieﬂy a 104 dilution of HY brain was diluted
into healthy hamster brain homogenate and subjected to 48 PMCA
cycles. Thereafter, an aliquot of the ampliﬁed material was diluted 10-
fold into healthy hamster brain homogenate and ampliﬁed again. This
procedure was repeated to reach a 1020 dilution of brain inoculum in
order to eliminate any brain derived PrPSc. A negative control groupwas
included consisting of normal urine samples subjected to the same
procedure of serial PMCA ampliﬁcation. The onset of clinical signs was
monitored as described in Section 2 and animals were considered sick
when they reach clinical level 4, characterized by extensive behavioral
problems including tremor of the head, ataxia, wobbling gait, head
bobbing, irritability, aggressiveness, jerks of the head and body and
spontaneous backrolls. At this time, animals were sacriﬁced to avoid
further pain and this is the number provided in the graph.and 100% speciﬁcity. Larger number of samples would be
needed to have a more accurate estimation of sensitivity and
speciﬁcity. It should be noted that although we have been able
recently to generate infectious PrPSc ‘‘de novo’’ (without the
addition of brain PrPSc), this requires modiﬁcation of some
PMCA parameters (unpublished observations). Under stan-
dard PMCA conditions, as those used in this study, spontane-
ous generation of infectious material does not occur within the
number of cycles used in this study.
To assess whether PrPSc present in urine has the conforma-
tional properties required to produce infectivity, in vitro gener-
ated PrPSc by PMCA starting from urine was injected into
wild-type hamsters. All inoculated animals developed clear
signs of HY prion disease at an average of 101.6 days after
inoculation (Fig. 3). The incubation period was not signiﬁ-
cantly diﬀerent to that obtained with a similar quantity of
PrPSc obtained from the brain of sick animals (97.8 days) or
PMCA-generated starting with HY brain inoculum (100.1
days) (Fig. 3). Conversely, none of the animals inoculated with
the equivalent material, but starting from urine of normal ani-
mals, developed disease. The disease exhibits the clinical char-
acteristics typical of HY hamster scrapie, including
hyperactivity, motor impairment, head wobbling, muscle
weakness and aggressiveness. Histopathological and biochem-
ical studies conﬁrmed that the disease produced from urinary
prions exhibited the typical characteristics of HY scrapie,
including spongiform degeneration (Fig. 4A), PrPSc accumula-
tion (Fig. 4B) and astroglyosis (Fig. 4C). The quantity and bio-
chemical characteristics of PrPSc were also indistinguishable
from HY prions (Fig. 4D). These data indicate that the infec-
tious properties and strain characteristics of prions are main-
tained in the urinary excreted PrPSc.4. Discussion
In this study we show that PrPSc with the capability to con-
vert PrPC into the misfolded form and produce disease is ex-
creted in urine by most of scrapie sick hamsters. Detection
of PrPSc in urine was possible only after extensive ampliﬁca-
tion by PMCA, suggesting that the quantity of prions in urine
is very small. As reported previously, 7 serial rounds of PMCA
enable detection of 1.3 ag of PrPSc in 20 ll of sample, which is
equivalent to a 1012 dilution from brain [11]. Considering that
in this study we detected the majority of the samples after 6 se-
rial rounds of PMCA, our estimation is that the quantity of
PrPSc in urine is between 1010 and 1011-fold lower than in
brain. Since the PrPSc concentration in the brain of a sick ham-
ster is around 50 lg/ml [11], we estimate that urine contains
approximately 0.5–5 fg/ml of PrPSc, expressed as monomer
concentration. Considering recent reports of the minimum size
of the most infectious prion particle corresponds to a PrPSc oli-
gomer containing around 20 molecules of PrP monomer [21],
we estimate that there are around 500–5000 PrPSc oligomeric
molecules in each ml of hamster urine. Comparison with the
quantity of PrPSc present in blood of sick hamsters, which is
around 109–1010 lower than in brain [10], we estimate that
the concentration of PrPSc in urine is in average 10-fold lower
than in blood.
PrPSc in urine retains the infectious properties, since injection
of the agent ampliﬁed from this ﬂuid produced a disease indis-
Fig. 4. Pathological and biochemical features of the disease produced by inoculation of PrPSc ampliﬁed from urine. As positive control we used
animals inoculated with brain-derived HY prions and as negative control we analyzed brains of uninfected hamsters. (A) Spongiform degeneration
was assessed by hematoxylin–eosin staining in diverse areas of the brain, including medulla, hippocampus and superior colliculus. (B) PrPSc
accumulation was studied by histological staining with anti-PrP 3F4 antibody as described in methods. (C) Reactive astrocytes were visualized by
immunological staining with antibodies against glial ﬁbrillar acidic protein (GFAP). (D) PrPSc accumulation was evaluated by Western blot after PK
digestion. Diﬀerent quantities of brain homogenate (dilutions 1:25, 1:50 and 1:100 with respect to the brain) were loaded into the gel. All samples
were treated with PK, except for the normal brain homogenate (NBH) were –PK is indicated. Results shown in panels A–D are representative of
several animals analyzed.
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Interestingly, animals inoculated with PrPSc ampliﬁed from the
HY strain (both from brain and urine) showed a similar incuba-
tion time as those injected with the same quantity of PrPSc from
sick brain. This is diﬀerent to what we obtained previously with
the 263K hamster prion strain in which the in vitro generated
protein had consistently lower infectivity per unit of PrPSc,
compared to the in vivo produced protein [9]. This is surprising
considering that 263K and HY strains are fairly similar in most
of the properties. So far, among the many prions from diﬀerent
species and strains we have ampliﬁed and shown to be infec-tious (data not shown), 263K is the only one that has a lower
speciﬁc infectivity when ampliﬁed in vitro. Currently, we do
not have an explanation for this phenomenon, but a recent pub-
lication from Kretschmars group reported that immobilization
of PMCA generated 263K PrPSc resulted in the same infectivity
than brain derived PrPSc [22]. This result suggests that the in vi-
tro produced protein was the same strain and the lower infectiv-
ity was due to a diﬀerent size distribution which results in a
more rapid biological clearance.
Our ﬁndings suggest that urine is a possible source of prion
transmission. Since urine produced by animals potentially
3166 D. Gonzalez-Romero et al. / FEBS Letters 582 (2008) 3161–3166infected with prions is permanently released and likely concen-
trated in environmental samples, such as soil and grass, this
route may prove very relevant for spreading of TSEs in wild
and captive animals such as cervids, sheep and cattle. It is
known that PrPSc is highly resistant to degradation and infec-
tivity can survive in the environment for a long time [23]. Re-
cent studies have shown that PrPSc adsorbs eﬃciently into soil
where it remains infectious and that both infectivity and PrPSc
can stay intact in soil for long periods of time [24–26]. Contam-
ination of soil with urinary prions may contribute to spreading
prion disease among animals, which are known to ingest large
amounts of soil, including cattle, sheep and cervids [24,26,27].
Worrisomely, the continuous excretion of urine and the extre-
mely high resistance of prions may lead to a progressive accu-
mulation of infectious material in the environment, with
potentially catastrophic consequences in the future.
One of the top priorities in the prion ﬁeld is to minimize fur-
ther spreading of TSEs to humans or animals by limiting the
exposure to contaminated material [7,14]. This is a diﬃcult
problem, because prion diseases have a long clinically-silent
incubation period in which infected individuals may unknow-
ingly transmit the disease. In addition, it is possible that many
individuals may remain as sub-clinical carriers during their en-
tire life, constituting a permanent source of prions [28]. There-
fore, the development and validation of procedures to detect
even the tiniest quantities of infectious material is of para-
mount importance [7,15]. Implementation of a large scale pro-
gram to screen animals at risk of infection and diagnosis of the
human population requires detection of prions in easily acces-
sible samples, such as blood or urine. Our results showing that
PrPSc can be detected in urine of a large proportion of infected
animals provide a promising avenue for a sensitive and non-
invasive biochemical diagnosis of prion diseases. Adaptation
of PMCA for detection of prions in urine of naturally infected
animals and humans may oﬀer a great possibility for routine
testing of prion infections.
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